Puma Biotechnology, Inc. (PBYI)
| Market Cap | 246.16M |
| Revenue (ttm) | 212.00M |
| Net Income (ttm) | 36.98M |
| Shares Out | 50.39M |
| EPS (ttm) | 0.74 |
| PE Ratio | 6.56 |
| Forward PE | 10.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 306,928 |
| Open | 5.030 |
| Previous Close | 5.060 |
| Day's Range | 4.880 - 5.060 |
| 52-Week Range | 2.540 - 6.120 |
| Beta | 1.16 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+43.3%) |
| Earnings Date | Nov 6, 2025 |
About PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast can... [Read more]
Financial Performance
In 2024, Puma Biotechnology's revenue was $230.47 million, a decrease of -2.19% compared to the previous year's $235.64 million. Earnings were $30.28 million, an increase of 40.23%.
Financial StatementsAnalyst Summary
According to one analyst, the rating for PBYI stock is "Strong Buy" and the 12-month stock price target is $7.0.
News
Puma Biotechnology: Step By Step In Making A Transition
Puma Biotechnology has been in something of a stasis for years, selling one drug with no new approvals while developing alisertib. The cash position remains strong enough to carry them through key rea...
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 5, 2025, the Compensation Committee of Puma's Board of Directors approved...
Puma Biotechnology, Inc. (PBYI) Q3 2025 Earnings Call Transcript
Puma Biotechnology, Inc. ( PBYI) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Mariann Ohanesian - Senior Director of Investor Relations Alan Auerbach - Founder, Chairman, P...
Puma Biotechnology Reports Third Quarter 2025 Financial Results
LOS ANGELES--(BUSINESS WIRE)--On 11/6/26, Puma Biotechnology issued its financials for Q3-2025 and hosted a conference to discuss operating results.
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue financials and host a conference call on Nov. 6, 2025 to discuss its results for the third quarter of 2025.
Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference
LOS ANGELES--(BUSINESS WIRE)--On 9/8/25, Puma Biotechnology CEO and President Alan Auerbach will present a company overview at the H.C. Wainwright Global Investment Conference.
Puma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call Transcript
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alan H. Auerbach - Founder, Chairman, President, CEO & Secretary Heather Blaber ...
Puma Biotechnology Reports Second Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--On 8/7/2025, Puma Biotechnology issued 2Q-2025 earnings results and followed with a conference call to discuss quarterly and year-to-date results.
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results
LOS ANGELES--(BUSINESS WIRE)--On August 7, 2025, Puma Biotechnology will host a conference call/webcast to review its financial results for the second quarter of 2025.
Puma Biotechnology: Updated Timelines And A Resurgence In Sentiment
Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Neratinib's combination with trastuzumab deruxtecan shows intriguing signals, espec...
Puma Biotechnology, Inc. (PBYI) Q1 2025 Earnings Call Transcript
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director Investor Relations Alan Auerbach - President & C...
Puma Biotechnology Reports First Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology release its 1Q'25 earnings results on May 8 after markets closed and followed with a conference call to discuss operating results.
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients
ATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today an...
Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced Phase I data of trastuzumab deruxtecan plus neratinib in solid tumors with HER2 alterations was presented at AACR 2025.
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 1Q-2025 results after market close on May 8, 2025, and follow with a conference call at 1:30 pm PT/4:30 pm ET.
Puma SE: Undervalued With Tailwinds Ahead
Puma SE is poised for a turnaround with strong growth plans in the US market and strategic athlete endorsements, leading me to assign a "Buy" recommendation. Despite recent subpar financial performanc...
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will present clinical data on its drug neratinib in a poster presentation on April 28 at the 2025 AACR Annual Meeting.
PUMA SE: This Is The Right Time To Buy
Puma SE's stock has dropped nearly 50% year-to-date, with an additional 20% decline following its Q4 earnings, creating a potential value opportunity for long-term investors. Despite consistent revenu...
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will prov...
Puma Biotechnology, Inc. (PBYI) Q4 2024 Earnings Call Transcript
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director-Investor Relations Alan Auerbach – Presid...
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 4Q and FY-2024 earnings results after the close on Feb. 27 and follow with a conference call to discuss results.
Puma Biotechnology to Present at TD Cowen's 45th Annual Health Care Conference
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will prov...
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 4Q and full year 2024 results on Feb. 27 and follow with a conference call at 1:30 p.m. PT/4:30 p.m. ET.
Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation
LOS ANGELES--(BUSINESS WIRE)--NCCN Guidelines for Cervical Cancer now include Puma's neratinib monotherapy for 2nd line or later use in patients with HER2-mutated tumors, Cat. 2A.
Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward
Puma Biotechnology focuses on expanding neratinib sales and developing alisertib for breast and lung cancers, despite recent stock declines. Neratinib sales are stagnant, but the company remains stabl...